- Neutropenia and Cancer Infections
- Antifungal resistance and susceptibility
- Fungal Infections and Studies
- Antibiotics Pharmacokinetics and Efficacy
- Acute Lymphoblastic Leukemia research
- Acute Kidney Injury Research
- Cancer Treatment and Pharmacology
- Antimicrobial Resistance in Staphylococcus
- Heart Failure Treatment and Management
- Childhood Cancer Survivors' Quality of Life
Children's National
2019
University of North Carolina Health Care
2017
University of North Carolina at Chapel Hill
2017
University of North Carolina Hospitals
2017
Increased toxicities have been identified with higher doses of pegaspargase (PEG-ASP) in adults. This has led to routine use a dose cap 3,750 IU for adult acute lymphoblastic leukemia (ALL) patients most institutions. In pediatric ALL patients, PEG-ASP is not capped. There concern at our institution that larger may result increased rates adverse effects and monitoring be warranted receiving greater than IU. The objective this study quantify the difference PEG-ASP-associated events between...
Antifungal prophylaxis is recommended for patients with acute lymphoblastic leukemia (ALL) during high-risk periods such as induction; however, increased vincristine toxicities have been reported the co-administration of triazole antifungals. We sought to determine whether vincristine-associated are higher among children ALL concurrently given fluconazole compared no prophylaxis.Using a retrospective cohort design, we reviewed records pediatric treated newly diagnosed from 2003 2013....
Abstract Purpose Results of a study rates acute kidney injury (AKI) in pediatric patients treated with vancomycin plus piperacillin–tazobactam or alternative antipseudomonal β-lactams (APBLs) are reported. Methods A retrospective, single-center cohort was performed. Pediatric were included the if they received combination therapy for at least 48 hours, had documented baseline and follow-up serum creatinine levels, trough concentration. The primary outcome frequency AKI, defined as 50%...